Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 3Phase NA 1Phase 2/3 1

Status

Completed 22Recruiting 13Terminated 8Unknown 5Not yet recruiting 4Active not recruiting 3Withdrawn 1Suspended 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 19Colorectal Neoplasms 19Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Advanced Solid Tumors 13Prostatic Neoplasms 12Advanced Solid Tumor 12Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Interventions

tazemetostat 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Lymphoma, T-Cell, Peripheral × Clear all
NCT07615283 2026-05-29

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

Sun Yat-sen University

Phase 1/2 Not yet recruiting
40 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Sun Yat-sen University

Phase 1/2 Not yet recruiting
43 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Ruijin Hospital

Phase 1/2 Not yet recruiting
48 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06757387 2025-01-03

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Peking University Cancer Hospital & Institute

Phase 1/2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡